- Report
- May 2024
- 129 Pages
Global
From €5794EUR$6,499USD£5,048GBP
- Report
- April 2024
- 185 Pages
Global
From €4012EUR$4,500USD£3,496GBP
- Report
- February 2022
- 195 Pages
Global
From €3209EUR$3,600USD£2,796GBP
- Report
- October 2022
- 177 Pages
From €3076EUR$3,450USD£2,680GBP
- Report
- October 2022
- 174 Pages
North America
From €3076EUR$3,450USD£2,680GBP
- Report
- October 2022
- 181 Pages
Middle East, Africa
From €3076EUR$3,450USD£2,680GBP
- Report
- October 2022
- 202 Pages
Europe
From €3076EUR$3,450USD£2,680GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €3076EUR$3,450USD£2,680GBP
- Report
- June 2025
- 250 Pages
Canada
From €2486EUR$2,789USD£2,166GBP
- Report
- May 2023
- 160 Pages
Global
From €4412EUR$4,949USD£3,844GBP
- Report
- September 2025
- 101 Pages
Global
From €3500EUR$4,206USD£3,156GBP
Humalog is a brand of insulin used to treat diabetes, a chronic endocrine and metabolic disorder. It is a fast-acting insulin that helps to control blood sugar levels in people with type 1 and type 2 diabetes. Humalog is a recombinant human insulin analog, meaning it is a synthetic version of the natural human insulin. It is administered via injection and works by helping the body to use glucose from the bloodstream. Humalog is used to help control blood sugar levels in people with diabetes, and can be used in combination with other diabetes medications.
Humalog is available in a variety of forms, including vials, pens, and cartridges. It is manufactured by Eli Lilly and Company, and is available in many countries around the world. Other companies that produce insulin analogs include Novo Nordisk, Sanofi, and Biocon. Show Less Read more